Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab

Nicholas G. Zaorsky, Yunguang Sun, Zixuan Wang, Joshua Palmer, Paolo M. Fortina, Charalambos Solomides, Maria Werner-Wasik, Adam P. Dicker, Rita Axelrod, Barbara Campling, Nathaniel Evans, Scott Cowan, Bo Lu

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

RTOG 0839 is a Phase II study of pre-operative chemoradiotherapy with or without panitumumab in potentially operable locally advanced non-small cell lung cancer (NS CLC). The investigational agent, panitumumab, is an anti-epithelial growth factor receptor (EGFR) antibody that improves progression-free survival in chemorefractory metastatic colorectal cancer (mCRC). Recently, both KRAS mutational status (i.e., mutated or not) and subtype (i.e., activating or inactivating) have been shown to be predictive of response to anti-EGFR therapy in mCRC. However, in NS CLC, it is unknown if KRAS mutational status or subtype predict benefit to anti-EGFR therapies because of unique genetic and epigenetic factors unique to each cancer. We present a patient with stage III NS CLC containing a KRAS G12D activating mutation who had a partial pathologic response, with disappearance of a minor KRAS mutant clone. This case suggests possible eradication of the G12D KRAS lung cancer clones by concurrent chemoradiation with panitumumab.

Original languageEnglish (US)
Pages (from-to)883-887
Number of pages5
JournalCancer Biology and Therapy
Volume14
Issue number10
DOIs
StatePublished - Oct 1 2013

Fingerprint

Growth Factor Receptors
Chemoradiotherapy
Non-Small Cell Lung Carcinoma
Mutation
Colorectal Neoplasms
Clone Cells
Epigenomics
Disease-Free Survival
Lung Neoplasms
Antibodies
Therapeutics
panitumumab
Neoplasms

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Zaorsky, Nicholas G. ; Sun, Yunguang ; Wang, Zixuan ; Palmer, Joshua ; Fortina, Paolo M. ; Solomides, Charalambos ; Werner-Wasik, Maria ; Dicker, Adam P. ; Axelrod, Rita ; Campling, Barbara ; Evans, Nathaniel ; Cowan, Scott ; Lu, Bo. / Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab. In: Cancer Biology and Therapy. 2013 ; Vol. 14, No. 10. pp. 883-887.
@article{c9bf3bbd97ae447b834654bd56699e65,
title = "Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab",
abstract = "RTOG 0839 is a Phase II study of pre-operative chemoradiotherapy with or without panitumumab in potentially operable locally advanced non-small cell lung cancer (NS CLC). The investigational agent, panitumumab, is an anti-epithelial growth factor receptor (EGFR) antibody that improves progression-free survival in chemorefractory metastatic colorectal cancer (mCRC). Recently, both KRAS mutational status (i.e., mutated or not) and subtype (i.e., activating or inactivating) have been shown to be predictive of response to anti-EGFR therapy in mCRC. However, in NS CLC, it is unknown if KRAS mutational status or subtype predict benefit to anti-EGFR therapies because of unique genetic and epigenetic factors unique to each cancer. We present a patient with stage III NS CLC containing a KRAS G12D activating mutation who had a partial pathologic response, with disappearance of a minor KRAS mutant clone. This case suggests possible eradication of the G12D KRAS lung cancer clones by concurrent chemoradiation with panitumumab.",
author = "Zaorsky, {Nicholas G.} and Yunguang Sun and Zixuan Wang and Joshua Palmer and Fortina, {Paolo M.} and Charalambos Solomides and Maria Werner-Wasik and Dicker, {Adam P.} and Rita Axelrod and Barbara Campling and Nathaniel Evans and Scott Cowan and Bo Lu",
year = "2013",
month = "10",
day = "1",
doi = "10.4161/cbt.25942",
language = "English (US)",
volume = "14",
pages = "883--887",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "10",

}

Zaorsky, NG, Sun, Y, Wang, Z, Palmer, J, Fortina, PM, Solomides, C, Werner-Wasik, M, Dicker, AP, Axelrod, R, Campling, B, Evans, N, Cowan, S & Lu, B 2013, 'Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab', Cancer Biology and Therapy, vol. 14, no. 10, pp. 883-887. https://doi.org/10.4161/cbt.25942

Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab. / Zaorsky, Nicholas G.; Sun, Yunguang; Wang, Zixuan; Palmer, Joshua; Fortina, Paolo M.; Solomides, Charalambos; Werner-Wasik, Maria; Dicker, Adam P.; Axelrod, Rita; Campling, Barbara; Evans, Nathaniel; Cowan, Scott; Lu, Bo.

In: Cancer Biology and Therapy, Vol. 14, No. 10, 01.10.2013, p. 883-887.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab

AU - Zaorsky, Nicholas G.

AU - Sun, Yunguang

AU - Wang, Zixuan

AU - Palmer, Joshua

AU - Fortina, Paolo M.

AU - Solomides, Charalambos

AU - Werner-Wasik, Maria

AU - Dicker, Adam P.

AU - Axelrod, Rita

AU - Campling, Barbara

AU - Evans, Nathaniel

AU - Cowan, Scott

AU - Lu, Bo

PY - 2013/10/1

Y1 - 2013/10/1

N2 - RTOG 0839 is a Phase II study of pre-operative chemoradiotherapy with or without panitumumab in potentially operable locally advanced non-small cell lung cancer (NS CLC). The investigational agent, panitumumab, is an anti-epithelial growth factor receptor (EGFR) antibody that improves progression-free survival in chemorefractory metastatic colorectal cancer (mCRC). Recently, both KRAS mutational status (i.e., mutated or not) and subtype (i.e., activating or inactivating) have been shown to be predictive of response to anti-EGFR therapy in mCRC. However, in NS CLC, it is unknown if KRAS mutational status or subtype predict benefit to anti-EGFR therapies because of unique genetic and epigenetic factors unique to each cancer. We present a patient with stage III NS CLC containing a KRAS G12D activating mutation who had a partial pathologic response, with disappearance of a minor KRAS mutant clone. This case suggests possible eradication of the G12D KRAS lung cancer clones by concurrent chemoradiation with panitumumab.

AB - RTOG 0839 is a Phase II study of pre-operative chemoradiotherapy with or without panitumumab in potentially operable locally advanced non-small cell lung cancer (NS CLC). The investigational agent, panitumumab, is an anti-epithelial growth factor receptor (EGFR) antibody that improves progression-free survival in chemorefractory metastatic colorectal cancer (mCRC). Recently, both KRAS mutational status (i.e., mutated or not) and subtype (i.e., activating or inactivating) have been shown to be predictive of response to anti-EGFR therapy in mCRC. However, in NS CLC, it is unknown if KRAS mutational status or subtype predict benefit to anti-EGFR therapies because of unique genetic and epigenetic factors unique to each cancer. We present a patient with stage III NS CLC containing a KRAS G12D activating mutation who had a partial pathologic response, with disappearance of a minor KRAS mutant clone. This case suggests possible eradication of the G12D KRAS lung cancer clones by concurrent chemoradiation with panitumumab.

UR - http://www.scopus.com/inward/record.url?scp=84885216119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885216119&partnerID=8YFLogxK

U2 - 10.4161/cbt.25942

DO - 10.4161/cbt.25942

M3 - Article

C2 - 23917487

AN - SCOPUS:84885216119

VL - 14

SP - 883

EP - 887

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 10

ER -